Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer by Verma, Vivek et al.




Practice patterns and outcomes of
chemoradiotherapy versus radiotherapy alone for
older patients with nasopharyngeal cancer
Vivek Verma
University of Nebraska Medical Center
Swati M. Surkar
Washington University School of Medicine in St. Louis
Amy C. Moreno
The University of Texas MD Anderson Cancer Center
Chi Lin
University of Nebraska Medical Center
Charles B. Simone II
University of Maryland at Baltimore
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Verma, Vivek; Surkar, Swati M.; Moreno, Amy C.; Lin, Chi; and Simone, Charles B. II, ,"Practice patterns and outcomes of





Numerous clinical trials have demonstrated survival 
improvements with the addition of chemotherapy to defini-
tive radiation therapy (RT) for head and neck cancers, 
as highlighted by the MACH- NC meta- analysis [1]. One 
important result of this study, however, was a decreasing 
benefit to chemotherapy with increasing age, which was 
independent of other covariates analyzed. Moreover, nearly 
40% of deaths in patients ≥71 years of age therein were 
not cancer- related. Although the meta- analysis did not 
evaluate toxicities, numerous studies have illustrated 
decreased tolerance of oncologic therapies by older patients 
[2–4].
A factor limiting applicability of the MACH- NC report 
was its specific exclusion of nasopharyngeal cancer (NPC). 
This neoplasm, rare in the United States but endemic in 
south China and north Africa, is most commonly treated 
with chemoradiotherapy (CRT) [5]. This paradigm is 
supported by the MAC- NPC meta- analysis, which 
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Abstract
Older patients are at increased risk of toxicities from aggressive oncologic therapy 
and of nononcologic death. A meta- analysis of non- nasopharyngeal head and 
neck cancers showed no statistical benefit in adding chemotherapy to radio-
therapy (RT) in older patients; another meta- analysis of RT versus chemoradio-
therapy (CRT) in NPC found advantages to CRT, but vastly under- represented 
patients ≥70 years old. This is the largest study to date evaluating outcomes of 
CRT versus RT alone in this population. The National Cancer Data Base (NCDB) 
was queried for primary nasopharyngeal cancer cases (2004–2013) in patients 
≥70 years old receiving RT alone or CRT. Patients with unknown RT/chemo-
therapy and T1N0 or M1 disease were excluded. Logistic regression analysis 
ascertained factors associated with CRT delivery. Kaplan–Meier analysis evaluated 
overall survival (OS) between both cohorts. Cox proportional hazards modeling 
determined variables associated with OS. In total, 930 patients were analyzed 
(n = 713 (77%) CRT, n = 217 (23%) RT). Groups were relatively balanced; 
CRT was less frequently delivered in patients with advancing age, lower nodal 
burden, and females (P < 0.05 for all). Median OS in the CRT and RT groups 
were 35.3 versus 20.0 months, respectively (P = 0.002). On multivariate analysis, 
independent predictors of OS included age, comorbidities, income and insurance 
status, tumor grade, and stage (P < 0.05 for all). Notably, receipt of chemo-
therapy independently predicted for improved OS (P = 0.036). CRT, compared 
to RT alone, was independently associated with improved survival in NPC pa-
tients ≥70 years old. CRT appears to be a promising approach in this population, 
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demonstrated an overall survival (OS) benefit of 6% at 
5 years with the addition of chemotherapy to RT [6]. 
However, that analysis notably underrepresented older 
patients, likely related to the median age of NPC patients 
being approximately 55 years (in the United States) [7]. 
Just 13% of the total MAC- NPC cohort was ≥60 years 
of age; although the proportion ≥70 years old was not 
reported, it is likely less than half of that figure.
As a result, optimal management for older (defined as 
≥70 years old herein) NPC patients with respect to the 
additional chemotherapy is currently not well defined. 
Although challenging to assess with single- or multi- 
institutional analyses owing to the relative rarity of older 
NPC patients, the National Cancer Data Base (NCDB) 
provides a unique resource with which to address this 
novel but clinically important issue. In this investigation, 
the largest such study to date, we evaluated national prac-
tice patterns and outcomes in older NPC patients treated 
with CRT versus RT alone.
Materials & Methods
The NCDB is a joint project of the Commission on Cancer 
(CoC) of the American College of Surgeons and the 
American Cancer Society, which consists of de- identified 
information regarding tumor characteristics, patient demo-
graphics, and patient survival for approximately 70% of 
the United States population [8–15]. All pertinent cases 
are reported regularly from CoC- accredited centers and 
compiled into a unified dataset, which is then validated. 
The NCDB contains information not included in the 
Surveillance, Epidemiology, and End Results database, 
including details regarding use of systemic therapy. The 
data used in the study were derived from a de- identified 
NCDB file (2004–2013). The American College of Surgeons 
and the CoC have not verified and are neither responsible 
for the analytic or statistical methodology employed nor 
the conclusions drawn from these data by the investiga-
tors. As all patient information in the NCDB database is 
de- identified, this study was exempt from institutional 
review board evaluation.
Inclusion criteria for this study were patients ≥70 years 
of age with newly- diagnosed nasopharyngeal cancer treated 
with RT for curative intent. The 70- year- old threshold 
was utilized because it is among the most commonly 
used cutoff to denote “older” patients in head/neck cancer 
as well as many other areas of oncology [16]; it is also 
close to the threshold utilized in the MACH- NC study 
[1]. T1N0 and M1 cases were excluded because CRT is 
not the consensus- based recognized treatment for these 
subsets; patients receiving any form of pharyngectomy 
were similarly removed because it is nonstandard for NPC 
and to isolate the effect of adding chemotherapy to RT 
[5]. Other exclusion criteria were incomplete staging infor-
mation, palliative care treatment, and unknown informa-
tion on RT and/or chemotherapy. In accordance with the 
variables in NCDB files, information collected on each 
patient broadly included demographic, clinical, and treat-
ment data.
All statistical tests were performed with SPSS software 
(IBM Corporation, Armonk, NY); tests were two- sided, 
with a threshold of P < 0.05 for statistical significance. 
Univariable and multivariable logistic regression were used 
to determine characteristics associated with receipt of CRT. 
All initially examined variables were considered for inclu-
sion into models for stepwise selection. Survival analysis 
(performed using Kaplan–Meier methodology) evaluated 
OS, defined as the interval between the date of diagnosis 
and the date of death or censored at last contact. Univariate 
and multivariate Cox proportional hazards modeling was 
utilized to evaluate predictors of OS.
Results
A complete flow diagram of patient selection is provided 
in Figure 1. In total, 930 patients met study analysis 
criteria. Table 1 displays notable clinical characteristics 
of the analyzed patients, most (74%) of whom were 
70–79 years of age. A total of 713 (77%) patients under-
went CRT, whereas 217 (23%) received RT alone. After 
univariable analysis was performed to assess factors asso-
ciated with receipt of CRT, multivariable assessment 
revealed that factors independently associated with 
decreased likelihood of CRT delivery were advancing age 
(P = 0.001), female gender (P = 0.014), and node- negative 
disease (P = 0.002). There was also a trend toward 
increasing CRT receipt in more recent years (2009–2013, 
P = 0.063).
Median follow- up was 23 months (range, 
0–129 months). Kaplan–Meier estimates comparing OS 
in patients that received RT alone versus CRT are illus-
trated in Figure 2; median OS in the respective cohorts 
were 20.0 (95% confidence interval (CI), 12.8–27.3) months 
and 35.3 (95% CI, 29.3–41.2) months (P = 0.002).
In the overall cohort, there were several predictors of 
OS on univariate analysis (Table 2). After multivariate 
adjustment for potential confounding factors (Table 2), 
factors independently associated with poorer OS included 
advancing age, comorbidity index, lower income, Medicare 
insurance (relative to private), poor/undifferentiated/ana-
plastic disease, and stage IV (M0) disease (P < 0.05 for 
all). Of note, receipt of CRT relative to RT alone inde-
pendently predicted for improved OS (hazard ratio, 0.721, 
95% CI, 0.532–0.979, P = 0.036).
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Discussion
To the best of our knowledge, this is the largest report 
assessing practice patterns and outcomes of RT with or 
without chemotherapy for elderly NPC patients. Our study 
of a large national database of this relatively uncommon 
clinical circumstance notably demonstrates that the addi-
tion of chemotherapy to RT is independently associated 
with greater survival in older patients, indicating that the 
benefit of chemotherapy in NPC may extend potentially 
to all ages.
A main message from our analysis is that causation is 
not implied; it could very well be that patients receiving 
RT alone were not healthy enough to receive additional 
chemotherapy, and hence they would naturally do worse 
and be at greater risk of dying from noncancer causes 
as mentioned above. Although the lack of endpoints such 
as cancer- specific survival and local/regional control in 
the NCDB hampers firm conclusions, there are several 
reasons to believe this bias may be relatively minimal. 
First, cohorts were relatively balanced, including no dif-
ferences in Charlson- Deyo comorbidity index (although 
this does not equate to performance status, it did inde-
pendently predict for OS on Cox multivariate analysis 
herein). In fact, because groups were overall quite balanced, 
Figure 1. Patient selection diagram.
Study populaon 
(n = 930)
No or unknown radiotherapy 
(n = 446)
Naonal Cancer Data Base 
















1607© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
CRT versus RT Alone for NPC in the ElderlyV. Verma et al.
Table 1. Characteristics of the overall cohort and factors associated with receiving chemoradiotherapy.







OR (95% CI) P- value OR (95% CI) P- value
Age (years)
Median (range) 75 (70–90) 79 (70–90) 0.542 (0.398–0.737) 0.001 0.860 (0.832–0.888) 0.001
Gender
Male 467 (66%) 110 (51%) 1.161 (1.125–1.198) 0.001 1.534 (1.089–2.161) 0.014
Female 246 (34%) 107 (49%) REF REF
Race
White 522 (73%) 166 (76%) REF
Black 65 (9%) 18 (8%) 0.871 (0.502–1.510) 0.622
Other 106 (15%) 26 (12%) 0.771 (0.485–1.226) 0.272
Unknown 20 (3%) 7 (3%) – –
Charlson deyo score1
0 541 (76%) 158 (73%) REF
1 129 (18%) 43 (20%) 1.141 (0.774–1.682) 0.504
≥2 43 (6%) 16 (7%) 1.274 (0.699–2.323) 0.429
Insurance type
Uninsured 3 (0%) 0 (0%) – –
Private 88 (12%) 29 (13%) 1.098 (0.699–1.727) 0.684
Medicaid/Other Government 
(non- Medicare)
31 (4%) 10 (5%) 1.075 (0.517–2.237) 0.846
Medicare 580 (81%) 174 (80%) REF
Unknown 9 (1%) 4 (2%) – –
Income (US dollars/year)
<$30,000 127 (18%) 44 (20%) REF
$30,000–$34,999 157 (22%) 52 (24%) 0.956 (0.601–1.521) 0.849
$35,000–$45,999 195 (27%) 57 (26%) 0.844 (0.537–1.326) 0.462
≥$46,000 226 (32%) 57 (26%) 0.728 (0.464–1.141) 0.166
Unknown 6 (1%) 7 (3%) – –
Location
Metro 596 (84%) 174 (80%) REF
Urban 85 (12%) 31 (14%) 1.249 (0.801–1.949) 0.327
Rural 9 (1%) 2 (1%) 0.761 (0.163–3.556) 0.761
Unknown 23 (3%) 10 (5%) – –
Percentage of adults in zip code without high school diploma
≥21% 137 (19%) 38 (18%) REF
13–20.9% 186 (26%) 61 (28%) 1.182 (0.745–1.875) 0.477
7–12.9% 233 (33%) 68 (31%) 1.052 (0.671–1.649) 0.825
<7% 149 (21%) 44 (20%) 1.065 (0.651–1.742) 0.803
Unknown 8 (1%) 6 (3%) – –
Facility type
Community 385 (54%) 134 (62%) REF
Academic 328 (46%) 83 (38%) 1.375 (1.008–1.877) 0.044
Facility location
Northeast 174 (24%) 39 (18%) REF
South 223 (31%) 76 (35%) 0.752 (0.461–1.227) 0.254
Midwest 175 (25%) 60 (28%) 1.144 (0.743–1.762) 0.541
West 141 (20%) 42 (19%) 1.151 (0.732–1.810) 0.542
Distance to treating facility (mi)
Median (range) 8 (0–2456) 7 (0–1736) 1.000 (0.999–1.001) 0.510
Year of Diagnosis
2004–2008 330 (46%) 117 (54%) 0.736 (0.543–0.999) 0.049 0.723 (0.514–1.017) 0.063
2009–2013 383 (54%) 100 (46%) REF REF
Tumor grade
Well or moderate 138 (19%) 38 (18%) REF
Poorly, undifferentiated, 
anaplastic
384 (54%) 99 (46%) 1.068 (0.701–1.628) 0.759
Unknown 191 (27%) 80 (37%) – –
(Continued)
1608 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
V. Verma et al.CRT versus RT Alone for NPC in the Elderly
there was relatively little indication for propensity match-
ing, which would have prohibitively eliminated sample 
size from an already limited patient population. 
Furthermore, there were only three variables significantly 
different between groups on multivariable logistic regres-
sion analysis (age, gender, and nodal status); of those 
three variables, the CRT cohort was younger but had a 
higher proportion of node- positive disease and males. 
Younger age has been shown to associate with more 
advanced disease [17]; node- positivity and male gender 
also correlate with poorer prognosis [18–20]. In this man-
ner, consistent with other work, it is plausible that chemo-
therapy potentially may have been given to a “higher- risk” 
population, and that there may be “true” benefits to adding 
chemotherapy [21, 22].
Despite the large dataset offered by the NCDB, one 
of its major limitations is a lack of toxicity assessment. 
To this extent, smaller retrospective reports of older NPC 
patients (which have employed varying definitions of 
“older/elderly”) suggest that despite the increase in acute 
toxicities when adding chemotherapy to RT, these may 
not be worse in severity from those experienced by younger 
patients [23, 24]. This is consistent with multiple studies 
in other head/neck neoplasms showing similar toxicities 
and/or outcomes in elderly patients as compared to their 
younger counterparts [2, 25–27]. Thus, we encourage 
judicious and individualized judgment when evaluating 
administration of CRT in elderly NPC patients; there 
will likely never be a “definitive answer” regarding aggres-
sive therapies (vs. lack thereof) in elderly patients, owing 
to retrospective patient selection biases and varying defi-
nitions of “older/elderly” patients from study to study.
We, therefore, propose that the term “older/elderly” 
should not be singularly defined by age, because these 
patients are intrinsically heterogeneous [28]. Rather, uti-
lization of many available measures to measure functionality 
(e.g., the Comprehensive Geriatric Assessment) and 







OR (95% CI) P- value OR (95% CI) P- value
T classification
X 21 (3%) 6 (3%) REF
1 147 (21%) 33 (15%) 1.577 (0.282–8.808) 0.604
2 203 (28%) 72 (33%) 0.708 (0.443–1.132) 0.149
3 137 (19%) 41 (19%) 1.119 (0.759–1.648) 0.571
4 205 (29%) 65 (30%) 0.944 (0.604–1.475) 0.800
N classification
0 193 (27%) 103 (47%) 0.396 (0.238–0.554) 0.001 0.252 (0.107–0.603) 0.002
1 237 (33%) 53 (24%) 0.630 (0.127–1.133) 0.238 0.570 (0.236–1.379) 0.213
2 196 (27%) 43 (20%) 0.661 (0.161–1.161) 0.263 0.614 (0.251–1.503) 0.263
3 52 (7%) 7 (3%) REF REF
Unknown 35 (5%) 11 (5%) – – – –
Group stage
II 94 (13%) 34 (16%) 1.370 (0.858–2.186) 0.187
III 233 (33%) 64 (29%) 1.040 (0.714–1.515) 0.837
IV 284 (40%) 75 (35%) REF
Unknown 102 (14%) 44 (20%) – – – –
Statistically significant P- values (P < 0.05) are in bold. Only values included in the final multivariable model are shown. CRT, chemoradiotherapy; RT, 
radiotherapy; OR, odds ratio; CI, confidence interval.
1The Charlson- Deyo index is a weighted score of comorbidities as defined by several medical codes.
Figure 2. Kaplan–Meier overall survival curve comparing those receiving 
radiotherapy alone (green) versus chemoradiotherapy (blue).
Table 1. (Continued).
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performance status (PS) is a more reliable way to divide 
“older/elderly” patients into the “functionally older/elderly” 
or “functionally young” [29]. For instance, Liu and col-
leagues did not find a benefit to adding chemotherapy 
to RT in NPC patients with high comorbidity indices 
[23]. This study was underpowered to confirm those 
findings. Nevertheless, these and other parameters are 
critically important in adequately selecting “elderly” patients 
that are “fit” to receive aggressive oncologic therapies.
Lastly, although one method to reduce toxicities of CRT 
is delivering chemotherapy and RT sequentially, we were 
unable to separately ascertain the benefit of concurrent 
versus sequential CRT. In our dataset, a large majority 
(77%) of CRT patients received chemotherapy and RT 
within 2 weeks of each other (two weeks being a previ-
ously utilized cutoff point for concurrent therapy in prior 
such publications [30]). Of the remaining 23% of the 
CRT cohort, timing of therapies was unknown in 7%, 
indicating that just 16% certainly received sequential CRT. 
This was much too small of a sample size to analyze 
separately in this study. Hence, induction chemotherapy 
followed by RT remains an attractive option in well- selected 
“older” NPC patients at higher risk of toxicities. 
Additionally, although the use of induction chemotherapy 
Table 2. Univariate and multivariate Cox proportional hazards model for overall survival.
Parameter
Univariate Multivariate
HR 95% CI P- value HR 95% CI P- value
Treatment group (CRT vs. RT alone) 0.735 0.606–0.892 0.002 0.721 0.532–0.979 0.036
Age (continuous) 1.053 1.036–1.069 0.001 1.063 1.037–1.090 0.001
Gender (male vs. female) 0.864 0.725–1.030 0.103
Race (black vs. white) 0.845 0.625–1.144 0.276
Race (others vs. white) 0.262 0.468–0.823 0.001
Charlson–Deyo score (0 vs. 2) 0.517 0.377–0.710 0.001 0.517 0.377–0.710 0.001
Charlson–Deyo score (1 vs. 2) 0.609 0.426–0.872 0.007 0.609 0.426–0.872 0.001
Insurance (uninsured vs. Medicare) 2.252 0.560–9.052 0.253 2.752 0.374–20.234 0.320
Insurance (private vs. Medicare) 0.613 0.459–0.852 0.001 0.553 0.359–0.852 0.007
Insurance (Medicaid/other government vs. Medicare) 0.629 0.387–1.022 0.061 0.700 0.377–1.298 0.257
Income (<$30,000 vs. $30,000–$34,999) 1.584 1.233–2.035 0.001 1.584 1.233–2.035 0.001
Income (<$30,000 vs. $35,000–$45,999) 1.403 1.097–1.794 0.019 1.403 1.097–1.703 0.007
Income (<$30,000 vs. ≥$46,000) 1.323 1.047–1.671 0.039 1.323 1.047–1.671 0.019
Location (urban vs. metro) 1.384 1.080–1.773 0.010
Location (rural vs. metro) 1.777 0.841–3.757 0.132
Percentage of adults in zip code without high school 
diploma (13–20.9% vs. ≥21%)
1.125 0.851–1.486 0.408
Percentage of adults in zip code without high school 
diploma (7–12.9% vs. ≥21%)
1.267 0.986–1.629 0.065
Percentage of adults in zip code without high school 
diploma (<7% vs. ≥21%)
1.049 0.820–1.341 0.704
Facility type (academic vs. community) 1.146 0.962–1.366 0.126
Facility location (South vs. Northeast) 1.143 0.867–1.507 0.344
Facility location (Midwest vs. Northeast) 1.289 1.001–1.658 0.049
Facility location (West vs. Northeast) 1.301 1.000–1.693 0.050
Distance to treatment facility (continuous) 1.000 0.999–1.000 0.515
Year of diagnosis (2004–2008 vs. 2009–2013) 0.981 0.815–1.182 0.843
Grade (poor/undifferentiated/anaplastic vs. well/
moderate)
1.691 1.356–2.110 0.001 1.510 1.163–1.962 0.002
T classification (x vs. 1) 0.326 0.104–1.022 0.055
T classification (x vs. 2) 0.404 0.311–0.525 0.001
T classification (x vs. 3) 0.494 0.397–0.614 0.001
T classification (x vs. 4) 0.532 0.411–0.698 0.001
N classification (0 vs. 1) 0.548 0.379–0.792 0.001
N classification (0 vs. 2) 0.695 0.481–1.003 0.052
N classification (0 vs. 3) 0.612 0.426–0.879 0.008
Group stage (II vs. IV) 0.497 0.358–0.691 0.001 0.530 0.359–0.783 0.001
Group stage (III vs. IV) 0.619 0.505–0.759 0.001 0.550 0.423–0.716 0.001
Statistically significant P values (P < 0.05) are in bold. Only values included in the final multivariate model are shown.
HR, hazard ratio; CI, confidence interval; CRT, chemoradiotherapy; RT, radiotherapy.
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followed by CRT could emerge as a new standard of care 
[31], the phase III trial deliberately excluded patients 
≥60 years of age owing to toxicity risks. However, ret-
rospective data of patients ≥60 years treated with CRT 
with or without induction chemotherapy showed no out-
come differences, with higher toxicities in those receiving 
induction therapy [32].
Although the NCDB provides a unique platform for 
studying this important clinical question, this investigation 
still has limitations. First, NCDB studies are inherently 
retrospective, with selection biases and lack of several 
endpoints as mentioned above. Second, NCDB does not 
keep track of precise chemotherapy details, including spe-
cific chemotherapeutic agents, reasons for withholding 
chemotherapy in RT alone patients (ie. related to toler-
ability vs. disease- related factors), or the number of cycles 
of chemotherapy received. Third, the NCDB does not 
allow for an assessment of subsequent lines of treatment 
(e.g., re- irradiation, further systemic and/or targeted ther-
apy), which could influence OS. Furthermore, the NCDB 
also does not provide details such as performance/func-
tional status, Epstein–Barr virus status, or radiotherapy 
field design/volumes/techniques. Fourth, a major limitation 
of this study was too few patients for a statistically reliable 
subset analysis of whether benefit to CRT is limited to 
those with advanced versus limited nodal disease. The 
NCDB is also unique to the United States and thus may 
not be representative to other areas of the world where 
NPC is endemic.
Conclusions
This is the largest study to date evaluating the utility of 
CRT, as compared to RT alone, for older (≥70 years old) 
patients with NPC. Administration of CRT was indepen-
dently associated with improved survival, but causation 
is not implied, and careful patient selection is necessary 
to balance treatment- related toxicity risks with potential 
oncologic benefits.
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